Shares of BioMarin Pharmaceutical (BMRN) have gained 2.1% over the past four weeks to close the last trading session at $67.38, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $98.28 indicates a potential upside of 45.9%.The average comprises 25 short-term price targets ranging from a low of $65 to a high of $138, with a standard deviation of $17.42. While the lowest estimate in ...